Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
[Cancer Research 59, 2136-2141, May 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spitzweg, C.
Right arrow Articles by Morris, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spitzweg, C.
Right arrow Articles by Morris, J. C.
[Cancer Research 59, 2136-2141, May 1, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Prostate-specific Antigen (PSA) Promoter-driven Androgen-inducible Expression of Sodium Iodide Symporter in Prostate Cancer Cell Lines1

Christine Spitzweg, Shaobo Zhang, Elizabeth R. Bergert, Maria R. Castro, Bryan McIver, Armin E. Heufelder, Donald J. Tindall, Charles Y. F. Young and John C. Morris2

Departments of Endocrinology [C. S., E. R. B., M. R. C., B. M., J. C. M.] and Urology [S. Z., D. J. T., C. Y. F. Y.], Mayo Clinic, Rochester, Minnesota 55905, and Medizinische Klinik, Klinikum Innenstadt, 80336 Munich, Germany [A. E. H.]

Currently, no curative therapy for metastatic prostate cancer exists. Causing prostate cancer cells to express functionally active sodium iodide symporter (NIS) would enable those cells to concentrate iodide from plasma and might offer the ability to treat prostate cancer with radioiodine. Therefore, the aim of our study was to achieve tissue-specific expression of full-length human NIS (hNIS) cDNA in the androgen-sensitive human prostatic adenocarcinoma cell line LNCaP and in subcell lines C4, C4-2, and C4-2b in vitro. For this purpose, an expression vector was generated in which full-length hNIS cDNA coupled to the prostate-specific antigen (PSA) promoter has been ligated into the pEGFP-1 vector (NIS/PSA-pEGFP-1). The PSA promoter is responsible for androgen-dependent expression of PSA in benign and malignant prostate cells and was therefore used to mediate androgen-dependent prostate-specific expression of NIS. In addition, two control vectors were designed, which consist of the pEGFP-1 vector containing the PSA promoter without NIS cDNA (PSA-pEGFP-1) and NIS cDNA without the PSA promoter (NIS-pEGFP-1). Prostate cancer cells were transiently transfected with each of the above-described expression vectors, incubated with or without androgen (mibolerone) for 48 h, and monitored for iodide uptake activity. In addition, stably transfected LNCaP cell lines were established for each vector. Prostate cells transfected with NIS/PSA-pEGFP-1 showed perchlorate-sensitive, androgen-dependent iodide uptake in a range comparable to that observed in control cell lines transfected with hNIS cDNA. Perchlorate-sensitive iodide uptake was not observed in cells transfected with NIS/PSA-pEGFP-1 and treated without androgen or in cells transfected with the control vectors. In addition, prostate cancer cell lines without PSA expression (PC-3 and DU-145) did not show iodide uptake activity when transfected with NIS/PSA-pEGFP-1. Western blotting of LNCaP and C4-2b cell membranes transfected with NIS/PSA-pEGFP-1 using a monoclonal antibody that recognizes the COOH-terminus of hNIS revealed a band with a molecular weight of 90,000 that was not detected in androgen-deprived cells or in cells transfected with the control vectors, as well as a minor band at Mr 150,000 in transiently transfected LNCaP cell membranes. In conclusion, tissue-specific androgen-dependent iodide uptake activity has been induced in prostate cancer cells by PSA promoter-directed NIS expression. This study represents an initial step toward therapy of prostate cancer with radioiodine.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Willhauck, B.-R. Sharif Samani, F.-J. Gildehaus, I. Wolf, R. Senekowitsch-Schmidtke, H.-J. Stark, B. Goke, J. C. Morris, and C. Spitzweg
Application of 188Rhenium as an Alternative Radionuclide for Treatment of Prostate Cancer after Tumor-Specific Sodium Iodide Symporter Gene Expression
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4451 - 4458.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
H. Zeng, Q. Wei, R. Huang, N. Chen, Q. Dong, Y. Yang, and Q. Zhou
Recombinant Adenovirus Mediated Prostate-Specific Enzyme Pro-Drug Gene Therapy Regulated by Prostate-Specific Membrane Antigen (PSMA) Enhancer/Promoter
J Androl, November 1, 2007; 28(6): 827 - 835.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Goel, S. K. Carlson, K. L. Classic, S. Greiner, S. Naik, A. T. Power, J. C. Bell, and S. J. Russell
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Blood, October 1, 2007; 110(7): 2342 - 2350.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Elisei, A. Vivaldi, R. Ciampi, P. Faviana, F. Basolo, F. Santini, C. Traino, F. Pacini, and A. Pinchera
Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2389 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Unterholzner, M. J. Willhauck, N. Cengic, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg
Dexamethasone Stimulation of Retinoic Acid-Induced Sodium Iodide Symporter Expression and Cytotoxicity of 131-I in Breast Cancer Cells
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 69 - 78.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Cengic, C. H. Baker, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg
A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy following Tissue-Specific Sodium Iodide Symporter Gene Expression
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4457 - 4464.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K.-H. Lee, H.-K. Kim, J.-Y. Paik, T. Matsui, Y. S. Choe, Y. Choi, and B.-T. Kim
Accuracy of Myocardial Sodium/Iodide Symporter Gene Expression Imaging with Radioiodide: Evaluation with a Dual-Gene Adenovirus Vector
J. Nucl. Med., April 1, 2005; 46(4): 652 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Dwyer, E. R. Bergert, M. K. O'Connor, S. J. Gendler, and J. C. Morris
In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter
Clin. Cancer Res., February 15, 2005; 11(4): 1483 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Miyagawa, M. Beyer, B. Wagner, M. Anton, C. Spitzweg, B. Gansbacher, M. Schwaiger, and F. M. Bengel
Cardiac reporter gene imaging using the human sodium/iodide symporter gene
Cardiovasc Res, January 1, 2005; 65(1): 195 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, T. Seregina, P. Seth, and C. Link Jr.
Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer
Clin. Cancer Res., October 15, 2004; 10(20): 6969 - 6976.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. V. Scholz, N. Cengic, B. Goke, J. C. Morris, and C. Spitzweg
Dexamethasone Enhances the Cytotoxic Effect of Radioiodine Therapy in Prostate Cancer Cells Expressing the Sodium Iodide Symporter
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1108 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Niu, A. W. Gaut, L. L. B. Ponto, R. D. Hichwa, M. T. Madsen, M. M. Graham, and F. E. Domann
Multimodality Noninvasive Imaging of Gene Transfer Using the Human Sodium Iodide Symporter
J. Nucl. Med., March 1, 2004; 45(3): 445 - 449.
[Abstract] [Full Text]

Home page
 BloodHome page
D. Dingli, K.-W. Peng, M. E. Harvey, P. R. Greipp, M. K. O'Connor, R. Cattaneo, J. C. Morris, and S. J. Russell
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
Blood, March 1, 2004; 103(5): 1641 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Barzon, M. Boscaro, and G. Palu
Endocrine Aspects of Cancer Gene Therapy
Endocr. Rev., February 1, 2004; 25(1): 1 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kakinuma, E. R. Bergert, C. Spitzweg, J. C. Cheville, M. M. Lieber, and J. C. Morris
Probasin Promoter (ARR2PB)-Driven, Prostate-Specific Expression of the Human Sodium Iodide Symporter (h-NIS) for Targeted Radioiodine Therapy of Prostate Cancer
Cancer Res., November 15, 2003; 63(22): 7840 - 7844.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Wang, J. K. Hu, A. Krol, Y.-P. Li, C.-Y. Li, and F. Yuan
Systemic dissemination of viral vectors during intratumoral injection
Mol. Cancer Ther., November 1, 2003; 2(11): 1233 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, S. Sharma, L. X. Zhu, T. Kogai, J. M. Hershman, G. A. Brent, S. M. Dubinett, and M. Huang
Nonradioactive Iodide Effectively Induces Apoptosis in Genetically Modified Lung Cancer Cells
Cancer Res., August 15, 2003; 63(16): 5065 - 5072.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Spitzweg, I. V. Scholz, E. R. Bergert, D. J. Tindall, C. Y. F. Young, B. Goke, and J. C. Morris
Retinoic Acid-Induced Stimulation of Sodium Iodide Symporter Expression and Cytotoxicity of Radioiodine in Prostate Cancer Cells
Endocrinology, August 1, 2003; 144(8): 3423 - 3432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Schipper, A. Weber, M. Behe, R. Goke, W. Joba, H. Schmidt, T. Bert, B. Simon, R. Arnold, A. E. Heufelder, et al.
Radioiodide Treatment after Sodium Iodide Symporter Gene Transfer Is a Highly Effective Therapy in Neuroendocrine Tumor Cells
Cancer Res., March 15, 2003; 63(6): 1333 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
O. Dohan, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C. S. Ginter, and N. Carrasco
The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance
Endocr. Rev., February 1, 2003; 24(1): 48 - 77.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. W. A. Smit, J. P. Schroder-van der Elst, M. Karperien, I. Que, M. Stokkel, D. van der Heide, and J. A. Romijn
Iodide Kinetics and Experimental 131I Therapy in a Xenotransplanted Human Sodium-Iodide Symporter-Transfected Human Follicular Thyroid Carcinoma Cell Line
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1247 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. A. Vorburger and K. K. Hunt
Adenoviral Gene Therapy
Oncologist, February 1, 2002; 7(1): 46 - 59.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Spitzweg, K. J. Harrington, L. A. Pinke, R. G. Vile, and J. C. Morris
The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3327 - 3335.
[Full Text] [PDF]

Home page
 JNMHome page
L. S. Zuckier, E. Dadachova, O. Dohan, N. Carrasco, Y. Nakamoto, T. Saga, T. Misaki, and S. Kosugi
The Endogenous Mammary Gland Na+/I- Symporter May Mediate Effective Radioiodide Therapy in Breast Cancer
J. Nucl. Med., June 1, 2001; 42(6): 987 - 987.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Spitzweg, M. K. O’Connor, E. R. Bergert, D. J. Tindall, C. Y. F. Young, and J. C. Morris
Treatment of Prostate Cancer by Radioiodine Therapy after Tissue-specific Expression of the Sodium Iodide Symporter
Cancer Res., November 1, 2000; 60(22): 6526 - 6530.
[Abstract] [Full Text]

Home page
 JNMHome page
Y. Nakamoto, T. Saga, T. Misaki, H. Kobayashi, N. Sato, T. Ishimori, S. Kosugi, H. Sakahara, and J. Konishi
Establishment and Characterization of a Breast Cancer Cell Line Expressing Na+/I- Symporters for Radioiodide Concentrator Gene Therapy
J. Nucl. Med., November 1, 2000; 41(11): 1898 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Boland, M. Ricard, P. Opolon, J.-M. Bidart, P. Yeh, S. Filetti, M. Schlumberger, and M. Perricaudet
Adenovirus-mediated Transfer of the Thyroid Sodium/Iodide Symporter Gene into Tumors for a Targeted Radiotherapy
Cancer Res., July 1, 2000; 60(13): 3484 - 3492.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1999 by the American Association for Cancer Research.